UCB (UCBJY) Stock Price, News & Analysis

Company Overview

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for people living with severe neurological and immunological diseases. The company operates internationally, serving patients and healthcare providers across North America, Europe and other global markets.

Its neurology portfolio includes treatments such as Keppra and Briviact for epilepsy, Vimpat for partial-onset seizures and Fintepla for certain severe seizure disorders. In immunology, UCB markets Cimzia for conditions including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and Crohn’s disease, as well as Bimzelx for several inflammatory skin and joint conditions.

UCB traces its origins to 1928, when it was established in Belgium as Union Chimique Belge. The company has since evolved from a diversified chemical and pharmaceutical business into a focused biopharmaceutical organization, with research and development activities centered primarily on neurology and immunology. UCB's shares trade on Euronext Brussels, and its American depositary shares trade over the counter under the symbol UCBJY.

Key Stats

• Today's Range: $120.56 to $121.50
• 50-Day Range: $117.07 to $142.80
• 52-Week Range: $116.49 to $168.76
• Volume: 40,370 shs
• Average Volume: 38,907 shs
• Market Capitalization: $45.80 billion
• P/E Ratio: N/A
• Dividend Yield: 0.44%
• Price Target: N/A
• Consensus Rating: Moderate Buy

UCB Stock Analysis - MarketRank™

UCB scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

UCB has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

UCB has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 14.89%

Earnings Growth

Earnings for UCB are expected to grow by 14.89% in the coming year, from $6.85 to $7.87 per share.

Price to Earnings Growth Ratio

UCB has a PEG Ratio of 1.02. PEG Ratios around 1 indicate that a company is correctly valued.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of UCB has been sold short.

Short Interest Ratio / Days to Cover

UCB has a short interest ratio ("days to cover") of 0.42, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in UCB has recently increased by 183.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

UCB has a dividend yield of 0.43%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

UCB does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, UCB will have a dividend payout ratio of 6.73% next year. This indicates that UCB will be able to sustain or increase its dividend.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: -0.07

News Sentiment

UCB has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for UCB this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, UCB insiders have not sold or bought any company stock.

Percentage Held by Institutions

UCB has minimal institutional ownership at this time.

Company Calendar

• Today: 9/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:UCBJY
• Previous Symbol: OTCMKTS:UCBJY
• CIK: 1290640
• Web: www.ucb.com
• Phone: (322) 559-9999
• Fax: 32-2559-9900
• Employees: 10,117
• Year Founded: 1928

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 17.69
• P/E Growth: 1.02
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 1.38
• Quick Ratio: 1.04

Sales & Book Value

• Annual Sales: $8.76 billion
• Price / Sales: 5.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 378,040,000
• Free Float: N/A
• Market Cap: $45.80 billion
• Optionable: Not Optionable
• Beta: 0.45